Acute coronary syndrome (ACS) is a significant contributor to both morbidity and mortality in Australia. Generally speaking, sufferers of ACS who live in rural areas and are treated at rural hospitals have poorer outcomes than those living in metropolitan areas.
Introduction
The purpose of this paper is to better understand the disparity facing rural and metropolitan populations with Acute Coronary Syndrome (ACS) in Australia. The paper is divided into three sections: 1) a review of the current guidelines and other tools used in the assessment of ACS, and a snapshot of how these have been incorporated clinically in Australia; 2) a comparison of the treatment modalities and clinical outcomes of metropolitan and rural populations; and 3) a discussion of factors affecting these outcomes and reasonable approaches to rectify the inequalities faced by rural populations.
Guidelines, adjuvant tools and the Australian experience of ACS in clinical practice
The current guidelines for the management of ACS were established by the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand (NHF/CSANZ) in 2006 and have since undergone two revisions in 2007 and 2011. 1, 2 While the guidelines have largely remained unchanged, the addendums document the results of recently published clinical trials relevant to the treatment of ACS and describe new recommendations in light of these findings.
The guidelines are structured around the stratification of ACS into ST-elevation myocardial infarction (STEMI) or Non-STelevation Acute Coronary Syndrome (NSTEACS) with the latter encompassing both Non-STEMI and the angina spectrum. NSTEACS can be further stratified into risk groups: high (NSTEACS-HR), intermediate (NSTEACS-IR), and low (NSTEACS-LR) risk. A STEMI is defined as either a persistent ST-elevation ≥1 mm in two contiguous limb leads; an ST elevation ≥2 mm in two contiguous chest leads; or a new left bundle branch block pattern. Treatment recommendations for STEMI favour Percutaneous Coronary Intervention (PCI) over thrombolysis where available within 0-12 hours of symptom onset. Treatment of NSTEACS is variable depending on troponin levels at presentation and six hours after presentation and patient risk group. Nevertheless, for all patients with NSTEACS, upgraded medical therapy and cardiac review or coronary cardiac unit (CCU) admission is advised. In all but the NSTEAC-IR with a negative stress test and NSTEAC-LR, angiography with a view to PCI or coronary artery bypass graft (CABG) is recommended in the subacute setting. 2 Risk stratification evidently plays a key role in assessing a patient with NSTEACS, and the NHF/CSANZ guidelines do identify specific requirements for each risk group. However, due to its emergent nature, the guidelines do not identify risk stratification for those with STEMI, where the focus is on determining the need for reperfusion rather than assessing risk. From a pragmatic point of view this presents some difficulties in establishing a comprehensive clinical approach to ACS, as accurate risk assessment could play an integral role in triage, management, and prognostication. For example, as recent studies have suggested, risk stratification may be used to identify those patients who require CCU admission-which has historically been based on criteria for reperfusion therapy rather than absolute risk-and in turn improve both the long and short-term clinical outcomes of ACS sufferers. Many clinical tools exist for risk stratification in ACS. The GRACE risk prediction tool is one such adjuvant that has been shown to be an excellent predictor of death, myocardial infarction and cumulative six-month risk of death in patients with ACS. 3 It can be used to facilitate triage and management of patients with NSTEACS as well as provide prognostication in STEMI. Born out of the ongoing global registry of acute coronary events (GRACE)-a prospective observational study involving, at the time, 94 hospitals across 14 countries, including Australia, with 43,810 patients-GRACE has been used to assess myriad outcomes in ACS. 4 The GRACE risk model uses age, heart rate, systolic blood pressure, creatinine, Killip Class of cardiac heart failure, and ACS presentation factors to establish risk and can be used in conjunction with the NHF/CSANZ guidelines to direct treatment in ACS.
settings used the recent ACACIA registry-a nationwide prospective audit of ACS in Australia that enrolled a cohort of 3,042 patients across 39 hospitals. 5 The authors identified varying compliance with guideline-recommended pharmacotherapies, reporting higher rates of aspirin and statin use; moderate rates of clopidogrel, beta-blocker and ACE-inhibitor/angiotensin receptor antagonist use; and low rates of glycoprotein IIb/IIIa inhibitor use. Regarding invasive management, the study found suboptimal rates of reperfusion therapy for STEMI across both rural and metropolitan populations. However, perhaps most disconcerting were the relatively low rates of early invasive management for NSTEACS-HR sufferers. 5 Treatment of these high-risk patients is paramount in an effort to combat disease progression and symptomatic presentation and thereby reduce the enormous burden-of-care in terms of morbidity, mortality, and cost of ACS. 8 While it appears that adherence to clinical guidelines is highest among STEMI sufferers, only half of NSTEACS-HR patients underwent guideline-recommended invasive management. 5 This is lower than rates found in other international registries, reflecting not only patient access and preference for treatment, but also lenient risk stratification by decision-making teams. 9 This snapshot of the experience of ACS in Australia highlights an inability to marry current ACS guidelines with risk assessment tools in the clinical approach to ACS.
The importance of time in ACS is another factor that has come under some scrutiny in the Australian clinical setting. Although, the advantage of PCI over thrombolysis has been well documented, more recent research has identified that timely reperfusion, not the modality of reperfusion is associated with significant outcome benefits. 10, 11 Although many definitions exist, we have understood "timely reperfusion" to mean those receiving thrombolysis within 30 minutes of presentation to first medical contact or PCI within 90 minutes of presentation to first medical contact. 12 With
Understanding ACS guidelines and the extent to which they are followed in Australia is essential in contextualising the next section of this paper, which considers the differences in the management and outcomes of ACS among Australia's rural and metropolitan populations.
Treatment modalities and clinical outcomes of metropolitan and rural populations
ACS is a significant contributor to both morbidity and mortality in Australia, responsible for approximately 75,000 hospitalisations and 10,000 deaths every year, with this figure projected to increase to 13,675 by 2020. 14 The spectrum of ACS represents the culmination of a disease process underscored by a list of well-documented pre-event risk factors, including hypertension, smoking, and diabetes. Often overlooked are post-event risk factors that contribute to increased morbidity and mortality in patients already hospitalised with ACS, one of which is living outside of a metropolitan region.
Generally speaking, sufferers of ACS who live in rural areas and are treated at rural hospitals have poorer outcomes than those living in metropolitan areas, making rurality a major risk factor for increased post-event morbidity and mortality. 15, 16 Death rates from coronary heart disease (CHD) are currently reported to be 10 per cent higher in regional areas and 15 per cent higher in remote areas than in major cities, 17 and various studies have highlighted the discrepancy between rural and metropolitan regions. Sexton and Sexton performed a descriptive analysis of data of 30-69-year-old Australians who died between 1986-1996 and found that, although deaths from coronary heart disease (CHD) declined overall in this period, mortality rates were up to 30 per cent higher in men and 21 per cent higher in women living 18 outside capital cities. Vu et al. compared in-hospital data again extrapolated from the ACACIA registry, a recent paper has identified that timely reperfusion was associated with a 78 per cent reduction in mortality; nevertheless, only 23.1 per cent of STEMI patients received timely reperfusion, and only 66.9 per cent of STEMI patients received any reperfusion at all. 11 Moreover, a state-wide study looking at call-to-needle (CTN) time-the time period between first notification by the patient and commencement of therapyacross Victoria, reported that only 61 per cent of patients received thrombolysis within the benchmark CTN time of 90 minutes and a CTN time of >90 minutes was associated with greater mortality (relative risk, 1.8). 13 Hence, it appears that despite having well-established and specific guidelines regarding the treatment of STEMI, national use of timely reperfusion remains poor and incomplete in practice.
mortality for acute myocardial infarction (AMI) between metropolitan and non-metropolitan hospitals in 1,665 patients and found that the odds of 7-day mortality in non-metropolitan hospitals was significantly higher than in metropolitan hospitals. 16 Beard and colleagues assessed mortality due to AMI and hospital admissions for ACS by postal area for NSW residents from 1996-2002, finding that higher levels of socioeconomic disadvantage-particularly in areas outside of major cities-were associated with increased risks of both ACS admissions and AMI mortality. 19 Many studies have convincingly shown an inverse relationship between social class and CHD, 20 and recent research both internationally and in Australia has shown that living in a region of socioeconomic disadvantage increases the probability of premature death over and above the socioeconomic characteristics of the citizens of that region. 21, 22 There is some temptation, therefore, to attribute the rural-metropolitan outcome gap for ACS wholly to socioeconomic status. However, mortality rates for CHD in Australia vary geographically, even after accounting for socioeconomic disadvantage. 23 Rurality itself is associated with remoteness from services, decreasing use of health services, 24 and an increased proportional representation of Indigenous people, in whom ACS is particularly prevalent. 23, 25 It is evident then that factors beyond socioeconomic status account for the apparent outcome gap that we see between rural and metropolitan settings, many of which are further discussed in the final section of this paper. Here we will continue to address the differences in treatment modalities for ACS between rural and metropolitan settings, as we believe that the inconsistencies and inadequacies in this area can be extrapolated to account for many of the poorer outcomes that are seen.
Ultimately, the time to reperfusion is critical in the acute treatment of ACS, but for optimal management, survivors also require continuing access to specific health services such as, among other things, a cardiologist, a pharmacist, and cardiac rehabilitation facilities. 5 Unfortunately, this is not always possible. As we have already seen in this paper, evidencebased guidelines are available for the management of ACS, but many inconsistencies exist in their delivery. The effective implementation of these guidelines is highly dependent upon the hospital to which the patient presents, as well as geographical location and the availability of adequate healthcare facilities in the patient's community. 26 The ARIA project used GPS technology to provide a geographical model of access to reperfusion facilities by the Australian population. 27 It found that 71 per cent of Australians live within an hour by road of a principal referral hospital with a cardiac catheterisation laboratory and to all aftercare services, meaning almost one-third of Australians are not able to access PCI within the time frames recommended in the guidelines. Similarly, it recognises that very few specialist cardiac services exist in rural and remote areas, meaning that a great deal of healthcare provision is left to the local GP.
The SNAPSHOT study specifically identifies that treatment inadequacies are more likely to occur outside of major hospitals: "Guideline-recommended investigations and therapies were provided less frequently to patients presenting to non-principal referral hospitals, regardless of patient transfers". 28 Previous studies have lent weight to this assertion and have highlighted differences both in the medication and procedural domains. Using data collected from 1,400 patients aged 25-69 admitted to hospital in the lower Hunter region in NSW, Lim, O'Connell, and Heller found that patients admitted to metropolitan hospitals with AMI had shorter lengths of admission and greater use of beneficial medications (e.g., aspirin, ACE-inhibitors) compared with patients admitted to regional hospitals. 29 Likewise, Vu et al. reported a difference in the prescription and use of beneficial cardiac medications between rural and metropolitan areas and found that the mortality difference between these two areas became negligible after adjustment for these medications was made. 16 Although medical thrombolysis is available for administration in all hospitals, availability of PCI is much more limited, with less than 10 per cent of emergency departments in Australia located in hospitals with cardiac catheterisation facilities, and even fewer in hospitals able to perform immediate PCI. 30 Using data from the NSW Acute Cardiac Care Project in 1996, Heller and colleagues identified higher rates of most cardiac procedures in metropolitan hospitals than in non-metropolitan hospitals for ACS patients. 30 Similarly, Beard and colleagues reported that after accounting for socioeconomic disadvantage, residents of Sydney had both a higher admission and intervention rate for ACS than residents elsewhere in NSW. 19 These findings reflect, at least partially, variations in access to health services, particularly the uptake of interventions such as revascularisation procedures.
Unfortunately, there is limited data comparing rural and metropolitan outcomes from the past few years. The approach to cardiac reperfusion is a rapidly changing landscape, and newer cardiac drugs are emerging each year. Further research into how these changes are affecting the discrepancies between rural and metropolitan outcomes is strongly encouraged.
Approaches to improving outcomes
Rural populations are known to have lower socioeconomic status than people in metropolitan areas. Lower levels of income, education, and literacy rates as well as higher unemployment all contribute to the generally higher mortality rates of these populations. 32 This has been shown to be no different for ACS sufferers, where it has been found that socioeconomic disadvantage increases the risk of ACS and related mortality largely due to inappropriate or inadequate management. 19 Compounding the difficulty of this social gradient in health is the greater population proportion of Indigenous Australians residing in rural and remote areas. Indigenous residents have generally poorer access to healthcare services, poorer nutrition, other lifestyle factors (including higher rates of alcohol consumption and smoking), and more comorbid conditions. 33, 34 Furthermore, Indigenous
Australians have been shown to take longer to present to medical aid. 33 Consequently, they tend to have poorer health outcomes than non-Indigenous Australians. 32 Specifically, CHD accounts for 14 per cent of the gap in the burden of disease; 35 with the age-adjusted mortality rate following AMI approximately 1.5 times higher for Indigenous people compared with non-Indigenous Australians. 36 Limited data comparing the specific outcomes of Indigenous and nonIndigenous populations in the rural setting makes it difficult to assess the severity of the discrepancies facing these geographic sub-groups; however, Indigenous males in outer regional and remote areas have been noted to be of significantly greater risk of mortality than their counterparts because of a lack of reporting of coronary heart disease. 37 Moreover, rural populations have generally lower rates of GP consultation, inadequate access to specialist services, and must travel greater distances in order to access appropriate health services. 38, 39 Reports by the Australian Institute of Health and Welfare (AIHW) highlight the disparity in services available to rural and remote populations compared to the metropolitan settings. 32 To try to meet the demand for services in these areas, clinicians are required to work longer hours, leaving many patients unable to access busy practices in a timely manner. 32 In addition, attending a general practice is prohibitively expensive for many people in rural Australia, with lower rates of bulk billing reported throughout these areas compared with metropolitan areas. 40 These factors have a major impact on the management of many chronic diseases underlying CHD and ACS, including regular follow-up of diabetic patients and the prescription of medications for blood pressure and cholesterol management, and thereby identifies a failure in primary and secondary prevention of this disease process. 32 Attention needs to be given to the affordability and accessibility of GP services for the effective prescribing of pharmacotherapy to patients and adequate surveillance of ACS patients once they are discharged from hospital.
As mentioned earlier, geographical accessibility is a major contributing factor to the poorer outcomes of ACS in rural populations. 32 An audit of findings from the ACACIA registry found that the greatest overall reduction in mortality was seen with a reduction in time for reperfusion. Nonetheless, the ACACIA registry interestingly found no statistical difference in the time to reperfusion when comparing rural and metropolitan patients. 11 Recent recommendations from the NHF have led some to suggest that GP thrombolytic therapy should be explored in areas beyond the reach of hospital services. 41 This notion has been supported by recent studies indicating that timely thrombolysis by GP-led emergency departments has similar results to thrombolytic therapy administered by specialist services. 42 These early initiatives have been found to be effective with significant improvements in outcomes in patients presenting with STEMI. 43 They present us with a pragmatic approach to reducing CTN time in ACS and eventually to potentially closing the gap between rural and metropolitan populations' access to reperfusion.
Lack of education regarding health practices and services is a frequently cited barrier to improving overall health outcomes in rural areas, and this may be responsible for the evidence suggesting that rural populations are less likely, or at the very least, delayed in seeking medical help when ACS symptoms arise. 44 In the context of ACS, however, improving education may not prove to be particularly efficacious. Recent studies, including two randomised controlled trials, have highlighted that knowledge of ACS is not enough to cause a patient to seek medical attention, and that education and counselling intervention do not lead to a reduction in time from onset of symptoms to arrival at the hospital. [45] [46] [47] Although advisable, it therefore seems improbable that improving health education in rural areas will alter prognosis and mortality for ACS sufferers. 47 Novel initiatives to allow earlier patient management and reperfusion that have been shown to improve prognosis and mortality in patients presenting with ACS include mobile thrombolysis units, which have been used throughout Europe for many years. 48 While Australia's geographical size may make this approach prohibitive for certain remote areas, this pre-hospital therapy reduces the ischaemic time of the myocardial tissue by decreasing therapy time from first symptoms and may be effective for both rural and metropolitan populations. This form of therapy, when appropriately administered by trained physicians has been shown to decrease CTN time and in turn may improve outcomes for ACS patients. [49] [50] Moreover, the use of these types of therapies by trained staff using well-established protocols could help in regions where travel time to thrombolysis facilities are lengthy. In these regions it could significantly reduce the time at which reperfusion therapy is commenced and thus contribute to improving outcomes and prognosis for ACS sufferers. 51 Within Australia, a pilot study into prehospital thrombolysis was undertaken in 2008, but was abandoned due to poor recruitment and improved CTN time through regional thrombolysis. 52 Despite its pitfalls, this study highlighted that the use of pre-hospital thrombolysis, undertaken by trained staff, could be an effective strategy in the Australian environment. Mobile thrombolysis may prove to be an interesting area for future studies into ACS.
Despite having well-established guidelines in the management of ACS in Australia, there is still scope for improvement once patients present to medical facilities in both urban and rural settings. Improvements to services must occur to ensure adequate use of evidence-based management. As has been already identified, improved assessment is integral for the determination of treatment and assessing risk. 3 Tools in risk stratification, like the GRACE risk model could help guide clinicians in triage, prognostication, and management of patients with ACS. [3] [4] This improvement to in-hospital assessment could consequently reduce morbidity and mortality in ACS patients. Another concern has been raised regarding the management of NSTEACS-HR and IR. These patients have been shown to have inadequate rates of early invasive management, leading to an increased likelihood of an acute coronary event in a 6-month period following their primary ACS. Failure to stratify risk in these patients has been implicated as the cause of this poorer outcome. [3] [4] The existing risk stratification tools may be useful in increasing early treatment of patients, resulting in improved outcomes in NSTEACS. Use of these tools in clinical trials on patients presenting with ACS is advised to assess their usefulness in treatment, particularly in the NSTEACS-HR and IR groups. Other services following patient discharge from hospital also need to improve. In particular, the maximisation of effective evidence-based pharmacotherapy is vital for reducing mortality and morbidity following an ACS in at-risk patients.
Conclusion
Disparities exist between the management and outcomes of rural and metropolitan populations experiencing ACS. While the causes of these discrepancies are multifactorial, in order to effectively reduce associated morbidity and mortality the onus falls to the healthcare system. Improvements in the management of ACS may be achieved through a continued reduction in call-to-needles time via the use of remote and mobile thrombolysis services as well as improvements in inhospital risk assessment in order to flag and investigate those at risk of ACS as well as effective pharmacotherapy post-ACS.
